Mitotic deacetylase complex (MiDAC) recognizes the HIV-1 core promoter to control activated viral gene expression

PLoS Pathog. 2024 May 23;20(5):e1011821. doi: 10.1371/journal.ppat.1011821. eCollection 2024 May.

Abstract

The human immunodeficiency virus (HIV) integrates into the host genome forming latent cellular reservoirs that are an obstacle for cure or remission strategies. Viral transcription is the first step in the control of latency and depends upon the hijacking of the host cell RNA polymerase II (Pol II) machinery by the 5' HIV LTR. Consequently, "block and lock" or "shock and kill" strategies for an HIV cure depend upon a full understanding of HIV transcriptional control. The HIV trans-activating protein, Tat, controls HIV latency as part of a positive feed-forward loop that strongly activates HIV transcription. The recognition of the TATA box and adjacent sequences of HIV essential for Tat trans-activation (TASHET) of the core promoter by host cell pre-initiation complexes of HIV (PICH) has been shown to be necessary for Tat trans-activation, yet the protein composition of PICH has remained obscure. Here, DNA-affinity chromatography was employed to identify the mitotic deacetylase complex (MiDAC) as selectively recognizing TASHET. Using biophysical techniques, we show that the MiDAC subunit DNTTIP1 binds directly to TASHET, in part via its CTGC DNA motifs. Using co-immunoprecipitation assays, we show that DNTTIP1 interacts with MiDAC subunits MIDEAS and HDAC1/2. The Tat-interacting protein, NAT10, is also present in HIV-bound MiDAC. Gene silencing revealed a functional role for DNTTIP1, MIDEAS, and NAT10 in HIV expression in cellulo. Furthermore, point mutations in TASHET that prevent DNTTIP1 binding block the reactivation of HIV by latency reversing agents (LRA) that act via the P-TEFb/7SK axis. Our data reveal a key role for MiDAC subunits DNTTIP1, MIDEAS, as well as NAT10, in Tat-activated HIV transcription and latency. DNTTIP1, MIDEAS and NAT10 emerge as cell cycle-regulated host cell transcription factors that can control activated HIV gene expression, and as new drug targets for HIV cure strategies.

MeSH terms

  • Gene Expression Regulation, Viral*
  • HIV Infections* / genetics
  • HIV Infections* / metabolism
  • HIV Infections* / virology
  • HIV-1* / genetics
  • HIV-1* / physiology
  • Humans
  • Promoter Regions, Genetic*
  • Viral Transcription
  • Virus Latency*
  • tat Gene Products, Human Immunodeficiency Virus / genetics
  • tat Gene Products, Human Immunodeficiency Virus / metabolism

Substances

  • tat Gene Products, Human Immunodeficiency Virus

Grants and funding

This work was supported by a CIHR Operating Grant (Funding Reference Number CHR-126637 to BB), and by The Canadian HIV Cure Enterprise Team Grant with funds from the CIHR in partnership with CANFAR and IAS (Grant number HIG-133050 to BB). The FQRNT awarded a research reintegration scholarship to EW. The Alice-E.-Wilson award of the CFUW was awarded to EW. NSERC awarded an Alexander Graham Bell Canada Graduate Scholarship to EW. The NSERC-funded CREATE program, RNA Innovation, awarded a graduate scholarship to MDR. An anonymous donor generously provided financial support to BB. BB is a member of the FRSQ-funded Centre de recherche du CHUS. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.